Biotech

Enveda Biosciences

Enveda Biosciences Raises $130M Series C

$130M Series C
Total Raised
2019
Founded
80-150
Employees
Boulder, CO
2 min read

Quick Facts

Valuation
Undisclosed

Enveda Biosciences Raises $130M Series C

Biotechnology company using AI and metabolomics to discover new drugs from natural products and medicinal plants

Key Highlights

  • Funding Amount: $130M Series C
  • Valuation: Undisclosed
  • Headquarters: Boulder, CO
  • Founded: 2019
  • Employees: 80-150
  • Total Raised: $175M

About the Funding Round

Enveda Biosciences has successfully closed $130M Series C in funding, marking a significant milestone in the company's growth trajectory. This investment will enable the company to accelerate product development, expand market reach, and strengthen its position in the biotech sector.

Investor Syndicate

The round was backed by a prestigious group of investors:

  • FPV Ventures
  • Kinnevik
  • Lux Capital

This diverse group of investors brings not only capital but also strategic expertise and valuable networks that will help Enveda Biosciences achieve its ambitious goals.

Market Opportunity

The biotech market continues to experience rapid growth, driven by increasing demand for innovative solutions and digital transformation across industries. Enveda Biosciences's unique approach and proven technology position it well to capture significant market share in the coming years.

Company Background

Founded in 2019 and headquartered in Boulder, CO, Enveda Biosciences has established itself as an innovative player in the biotech space. With 80-150 employees, the company has built a strong team focused on delivering exceptional value to customers.

Next Steps

With this new funding, Enveda Biosciences plans to:

  • Accelerate product development and innovation
  • Expand into new markets and geographies
  • Grow the team across engineering, sales, and operations
  • Strengthen partnerships with key industry players
  • Scale infrastructure to support rapid growth

Industry Impact

This funding round represents a strong vote of confidence in Enveda Biosciences's vision and execution. The investment will help drive innovation in the biotech sector and create new opportunities for customers and partners.


For more information about Enveda Biosciences, visit their website or contact their press office.

Key Investors

FPV Ventures
Venture Capital
Venture capital firm
Kinnevik
Strategic Investor
Swedish investment firm
Lux Capital
Venture Capital
Venture capital firm backing science and technology ventures

About the Author

Sarah Kim
Sarah Kim
Healthcare and biotech investment analyst with expertise in Series B+ rounds and strategic partnerships.